Home

Novo Nordisk A/S Common Stock (NVO)

53.75
+1.92 (3.71%)
NYSE · Last Trade: Aug 18th, 11:07 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close51.83
Open54.60
Bid53.90
Ask54.00
Day's Range53.75 - 54.99
52 Week Range45.05 - 139.74
Volume32,445,482
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield2.198 (4.09%)
1 Month Average Volume27,080,202

Chart

About Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk A/S is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals, primarily in the fields of diabetes care and hormone replacement therapy. With a strong emphasis on research and development, the company aims to improve the lives of patients with chronic conditions by providing high-quality medications and medical devices. Novo Nordisk is recognized for its comprehensive approach to diabetes management, including insulin products and modern delivery systems, while also expanding its portfolio to address other serious conditions, such as obesity and rare blood disorders. The company operates in numerous countries, combining expertise in biotechnology with a commitment to sustainability and corporate responsibility. Read More

News & Press Releases

Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4marketbeat.com
A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.
Via MarketBeat · August 18, 2025
Autonomous Vehicles Hit an Inflection Point; GPT-5 Is Herefool.com
Motley Fool Money checks in on some stock market news.
Via The Motley Fool · August 18, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · August 18, 2025
Why Weight-Loss Drugmaker Novo Nordisk’s Stock Is Rising Premarket Todaystocktwits.com
Via Stocktwits · August 18, 2025
Stocks Muted Ahead Trump-Zelenskyy Meeting, First Solar Jumps: What's Moving Markets Monday?benzinga.com
Investor risk sentiment paused at the start of the week, as markets awaited details expected to emerge later when President Donald Trump meets with Ukrainian President Volodymyr Zelenskyy and European leaders.
Via Benzinga · August 18, 2025
Dayforce, Applied Digital, GoodRx, First Solar, TeraWulf: Stocks Making The Biggest Moves Todaystocktwits.com
Dayforce shares skyrocketed 26% in Monday’s midday trade after reports suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.
Via Stocktwits · August 18, 2025
Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lowsbenzinga.com
Novo Nordisk is showing signs that a comeback might be on the horizon after it hit the lows of its 52-week trading range.
Via Benzinga · August 18, 2025
Market Movers: UnitedHealth, Intel, and Novo Nordisk Among Top Performers Reshaping the Financial Landscape
The financial markets are abuzz with significant movements across various sectors, driven by a confluence of strategic investments, groundbreaking regulatory approvals, and the enduring influence of retail investor sentiment. From Warren Buffett's latest healthcare bet to the Trump administration's potential foray into semiconductor manufacturing, and a major pharmaceutical breakthrough, these
Via MarketMinute · August 18, 2025
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrocketsbenzinga.com
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.
Via Benzinga · August 18, 2025
Why Novo Nordisk Stock Popped Mondayfool.com
Novo Nordisk stock looks so cheap, any good news at all can make it pop.
Via The Motley Fool · August 18, 2025
Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patientsstocktwits.com
The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost.
Via Stocktwits · August 18, 2025
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharmainvestors.com
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.
Via Investor's Business Daily · August 18, 2025
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 18, 2025
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK - August 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S (NYSE: NVO) of a class action securities lawsuit.
Via TheNewswire.com · August 18, 2025
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) between May 7, 2025 and July 28, 2025, inclusive.
By Bernstein Liebhard LLP · Via GlobeNewswire · August 18, 2025
Dow Futures Decline After Recent Rally, All Eyes On Powell’s Jackson Hole Speech: NVO, UNH, FSLR, RUN, PANW Among Stocks To Watchstocktwits.com
Via Stocktwits · August 18, 2025
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Diseasebenzinga.com
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
Via Benzinga · August 18, 2025
1 Stock Down 40% This Year to Buy and Holdfool.com
This might be a wonderful entry point for long-term investors.
Via The Motley Fool · August 17, 2025
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · August 17, 2025
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitorsfool.com
The drugmaker's recent dip could also be a buying opportunity.
Via The Motley Fool · August 17, 2025
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT), SelectQuote, Inc. (NYSE:SLQT) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · August 16, 2025
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.fool.com
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.
Via The Motley Fool · August 16, 2025
Why Novo Nordisk Flew Almost 3% Higher on Fridayfool.com
It seems to be holding off on price adjustments demanded by President Trump.
Via The Motley Fool · August 15, 2025
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 15, 2025
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
NEW YORK - August 15, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S (NYSE: NVO) of a class action securities lawsuit.
Via TheNewswire.com · August 15, 2025